NUDT15 and inflammatory bowel disease: A recent study also assessed the cost-effectiveness of pretreatment NUDT15 pharmacogenetic testing in IBD patients, indicating that a combined TPMT and NUDT15 analysis is the most cost-effective option among European participants and recommended to consider reflex NUDT15 testing for patients exhibiting reduced TPMT activity or the loss-of-function genotype [23].